Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,000 shares of the medical research company's stock after purchasing an additional 19,000 shares during the period. Ilmarinen Mutual Pension Insurance Co's holdings in Edwards Lifesciences were worth $4,886,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its position in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB boosted its position in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after purchasing an additional 300,000 shares during the period. Sivik Global Healthcare LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences during the fourth quarter worth $4,845,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Truist Financial lowered their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $79.81.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,853 shares of company stock valued at $4,534,247. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.56 during mid-day trading on Friday, hitting $68.82. 1,482,930 shares of the stock were exchanged, compared to its average volume of 4,884,162. The company has a market capitalization of $40.46 billion, a P/E ratio of 9.88, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a 50-day simple moving average of $71.36 and a 200 day simple moving average of $70.67. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.